Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.
Method Article
Here, we present protocols for working with Limosilactobacillus reuteri DSM20016, detailing growth, plasmid transformation, colony PCR, fluorescent reporter protein measurement, and limited plasmid mini-prep, as well as common issues and troubleshooting. These protocols allow the measurement of reporter proteins in DSM20016, or confirmation via colony PCR if no reporter is involved.
Lactobacillus were an incredibly large, diverse genus of bacteria comprising 261 species, several of which were commensal strains with the potential for use as a chassis for synthetic biological endeavors within the gastrointestinal tract. The wide phenotypic and genotypic variation observed within the genus led to a recent reclassification and the introduction of 23 novel genera.
Due to the breadth of variations within the old genera, protocols demonstrated in one member may not work as advertised with other members. A lack of centralized information on how exactly to manipulate specific strains has led to a range of ad hoc approaches, often adapted from other bacterial families. This can complicate matters for researchers starting in the field, who may not know which information does or does not apply to their chosen strain.
In this paper, we aim to centralize a set of protocols with demonstrated success, specifically in the Limosilactobacillus reuteri strain designation F275 (other collection numbers: DSM20016, ATCC23272, CIP109823), along with troubleshooting advice and common issues one may encounter. These protocols should enable a researcher with little to no experience working with L. reuteri DSM20016 to transform a plasmid, confirm transformation, and measure system feedback in a plate reader via a reporter protein.
The genus Lactobacillus were historically classified as gram-positive, rod-shaped, non-spore-forming, either facultative anaerobes or microaerophiles that break sugars down to primarily produce lactic acid1. These loose criteria led to Lactobacillus being, phenotypically and genotypically, an extremely diverse genus. This broad categorization resulted in the genus being reclassified, introducing 23 novel genera in 20202.
The old, broader genus included major commensal and probiotic species generally regarded as safe (GRAS) for consumption3. The Lactobacillaceae family maintains a public perception of being 'good bacteria' due to many reported health benefits bestowed via the consumption of various strains4,5,6,7. The ease with which they can navigate the gastrointestinal tract8 and their public acceptance combine to position Lactobacillaceae strains as strong candidates as chassis organisms for ingestible medicinal, therapeutic, or diagnostic applications.
The wide range of characteristics present within the Lactobacillaceae family has led to a situation in which there is no de facto model-organism strain; research groups have tended to select species with the properties most relevant to their particular aims. (For example, dairy fermentation labs could choose L. lactis; studies of vegetable fermentation might select L. plantarum; research on probiotics might focus on L. acidophilus; and so on.)
This same wide range of characteristics across species has led to an accumulation of protocols and procedures that may work well for one subset of the Lactobacillaceae family, but require optimization to work efficiently (or perhaps to function at all) in others9. This need for optimization between family members and even within members of the same species can frustrate the efforts of unfamiliar researchers. Protocols published in the methods sections of papers can also include their own modifications10, leading to fragmented, decentralized protocol collections.
L. reuteri is considered a widely vertebrate commensal, found consistently in mammalian, avian11 and fish12 gastrointestinal (GI) tracts. L. reuteri sub-strains are often genetically specialized, via mucus adhesion protein adaptation, to more permanently colonize specific native hosts8,11,13. GI tract Limosilactobacillus species can be isolated in hosts outside their native host, but tend more toward a transient nature8.
Due to human-host specialization, L. reuteri DSM20016 positions itself very well as a chassis for diagnostic or therapeutic applications at any point in the human GI tract, and the strain DSM20016 could provide a longer-lasting window of effect for interventions when compared to more transitory strains.
In this paper, we outline a series of protocols with demonstrated effectiveness in Limosilactobacillus reuteri (strain designation: F275; other collection numbers: DSM20016, ATCC23272, CIP109823), along with centralized information on the strain from other sources to aid in molecular and systems biology applications. Procedures laid out herein should enable a researcher with no prior experience to culture L. reuteri, create electrocompetent stocks, select transformed colonies, confirm transformation via colony polymerase chain reaction (PCR), and measure designed system response via fluorescent reporter proteins.
We note that related protocols have covered CRISPR-Cas9 assisted ssDNA genome recombineering in L. reuteri (strain: ATCC-PTA-6475)14, and CRSIPR-Cas9 nickase-assisted genome editing in multiple non-L. reuteri, Lactobacillaceae family stains15,16; these do not, however, address the L. reuteri DSM20016 strain that is our focus here.
1. Preparing L. reuteri DSM20016 electrocompetent cells
NOTE: This is based on a protocol by Berthier et al.17, with centrifugation speeds informed by Rattanachaikunsopon et al.18.
2. Electroporation of L. reuteri
NOTE: Avoid pipetting as much as possible in the following steps. Inclusion of a control electroporation, with no plasmid added, is advised to ensure the antibiotic selection is adequate.
3. Measurement of the acid-resistant fluorescent reporter protein mCherry2
4. Confirmation of plasmid uptake via colony PCR
5. Mini-prep protocol for L. reuteri , followed by PCR to confirm plasmid presence
NOTE: Protocol intended for use with the mini-prep kit listed in the Table of Materials.
Transformation efficiencies
L. reuteri does not require a dcm-/dam- non-methylated plasmid, as observed for other Lactobacillaceae19,20 (see Figure 1). Electroporation of L. reuteri DSM20016 with 10 µL of the 8.5 kb plasmid pTRKH3_mCherry2 (pAMβ1 theta origin of replication) should give transformation efficiencies of roughly 80 colony forming units (CFU...
The most critical step for the transformation of L. reuteri DSM20016 is the generation of anaerobic growth conditions after transformations are plated; colonies gained in aerobic conditions are only very occasional and generally fail to grow when inoculated in MRS broth. Plating the entire recovery volume should also be practiced to maximize the probability of colony growth. Even with these two critical steps, transformation efficiency is still a limitation on experimentation, as expected colonies can number as ...
No conflicts of interest exist.
We greatly appreciate the valuable advice provided by Prof. J.P. van Pijkeren (University of Wisconsin-Madison), whose guidance on working with L. reuteri ATCC PTA 6475 provided a foundation for the methods described here.
Name | Company | Catalog Number | Comments |
1 kb Plus DNA Ladder | NEB | N3200L | |
1mL Spectrophotometer cuvettes | Thomas Scientific | 1145J12 | |
Agarose | BioShop | AGR001 | |
Allegra X-15R (refrigerated centrifuge) | Beckman Allegra | N/A | No longer in production |
AnaeroGen 2.5 L Sachet | Thermo Scientific | OXAN0025A | |
BTX, ECM 399 electroporation system | VWR | 58017-984 | |
Centrifuge tubes (50 mL) | FroggaBio | TB50-500 | |
DNA gel x6 loading dye | NEB | B7024S | |
Electroporation cuvette | Fisherbrand | FB101 | |
Erythromycin | Millipore Sigma | E5389-5G | |
Gel electroporation bath/dock | VWR | 76314-748 | |
Glycerol | BioShop | GLY001 | |
Limosilactobacillus reuteri | Leibniz Institute DSMZ | DSM20016 | Strain designation F275 |
Lysozyme | BioShop | LYS702.5 | |
Microcentrifuge tubes (1.7 mL) | FroggaBio | LMCT1.7B | |
Miniprep kit (Qiagen) | Qiagen | 27106 | slpGFP replaced with constitutive, codon optimised, mCherry2 reporter protein |
MRS Broth (Dehydrated) | Thermo Scientific | CM0359B | |
Mutanolysin | Millipore Sigma | M9901-5KU | |
NaOH | Millipore Sigma | 1064691000 | |
P100 Pipette | Eppendorf | 3123000047 | |
P1000 Pipette | Eppendorf | 3123000063 | |
P2.5 Pipette | Eppendorf | 3123000012 | |
P20 Pipette | Eppendorf | 3123000039 | |
P200 Pipette | Eppendorf | 3123000055 | |
PCR tubes | FroggaBio | STF-A120S | |
Personal benchtop microcentrifuge | Genlantis | E200100 | |
Petri dishes | VWR | 25384-088 | |
PTC-150 Thermal Cycler | MJ Research | N/A | No longer in production |
pTRKH3_slpGFP (modified) | Addgene | 27168 | |
SPECTRONIC 200 Spectrophotometer | Thermo Scientific | 840-281700 | |
Storage microplate | Fisher Scientific | 14-222-225 | |
Sucrose | BioShop | SUC507 | |
TAE Buffer 50x | Thermo Scientific | B49 | |
Vortex | VWR | 58816-121 | No longer in production |
VWR 1500E incubator | VWR | N/A | No longer in production |
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone